Ting Ning-Shiuan, Ding Dah-Ching, Wei Yu-Chi
Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, Tzu Chi University, Hualien 970, Taiwan.
Institute of Medical Sciences, College of Medicine, Tzu Chi University, Hualien 970, Taiwan.
J Clin Med. 2022 Jun 19;11(12):3519. doi: 10.3390/jcm11123519.
This retrospective study aimed to compare the safety and efficacy of Prostin E2 and Propess for the induction of labor (IOL) in nulliparous women between January 2018 and October 2021. The inclusion criteria were nulliparous, singleton, >37 weeks’ gestation, cephalic presentation with an unfavorable cervix (Bishop score ≤ 6), no signs of labor, and use of one form of dinoprostone (Prostin E2 or Propess) for IOL. The cesarean section (C/S) rate and induction-to-birth interval were the main outcome measures. In total, 120 women were recruited. Sixty (50%) patients received Propess and 60 (50%) received repeated doses of Prostin E2. The Prostin E2 and Propess groups had similar patient characteristics, but the Bishop score was significantly higher in the Propess group than in the Prostin E2 group; therefore, multivariate analysis was conducted, and the Bishop score was not associated with the induction-to-birth interval. The C/S rate was not significantly different between the two groups, but the Propess group achieved a shorter induction-to-birth interval, a higher rate of vaginal delivery in 24 h, and a lower number of vaginal examinations than the Prostin E2 group. Propess was effective and safe in IOL and could be an option for cervical ripening in nulliparous pregnancy.
这项回顾性研究旨在比较2018年1月至2021年10月间普罗斯特E2(Prostin E2)和普贝生(Propess)在初产妇引产中的安全性和有效性。纳入标准为初产妇、单胎、妊娠>37周、头先露且宫颈条件不佳(bishop评分≤6)、无临产迹象,以及使用一种地诺前列酮制剂(普罗斯特E2或普贝生)进行引产。剖宫产率和引产至分娩间隔是主要观察指标。共招募了120名女性。60名(50%)患者接受了普贝生,60名(50%)接受了重复剂量的普罗斯特E2。普罗斯特E2组和普贝生组患者特征相似,但普贝生组的bishop评分显著高于普罗斯特E2组;因此,进行了多因素分析,bishop评分与引产至分娩间隔无关。两组的剖宫产率无显著差异,但普贝生组的引产至分娩间隔更短,24小时内阴道分娩率更高,阴道检查次数比普罗斯特E2组少。普贝生在引产中有效且安全,可作为初产妇妊娠宫颈成熟的一种选择。